FDA Grants Priority Review to ENHERTU for Early Breast Cancer Use
WILMINGTON, DE — The U.S. Food and Drug Administration has accepted and granted Priority Review to a supplemental application for ENHERTU, a breast cancer treatment developed by AstraZeneca and Daiichi …
FDA Grants Priority Review to ENHERTU for Early Breast Cancer Use Read More